SOPH SOPH
Company Profile ↓Company Overview
SOPH (SOPH) is a publicly traded company listed on with a market capitalization of $562.72M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 17.6% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $77.27M (+18.6% YoY); net profit $-79.00M.
- Trailing 12 Months Year-on-year growth — revenue +18.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 17.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 17.56% |
| 1 Year: | 18.56% |
Stock Price Performance
| 1 Year: | +99.37% |
| 6 Months: | +25.50% |
| 3 Months: | +24.26% |
| 1 Month: | +15.81% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)57.89 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 17.6% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 17.78M | 18.32M | 19.46M | 21.71M | 21.69M |
| Cost of Revenue | - | 5.57M | 6.05M | 6.55M | 7.01M | 6.94M |
| Gross Profit | - | 12.21M | 12.27M | 12.91M | 14.69M | 14.75M |
| Operating Expenses | - | 28.24M | 30.76M | 30.77M | 33.21M | 32.03M |
| Operating Income | - | -16.04M | -18.49M | -17.86M | -18.52M | -17.28M |
| EBITDA | - | -13.93M | -18.72M | -15.29M | -15.46M | -14.65M |
| Interest Expense | - | 659.00K | 559.00K | 1.66M | 1.67M | 1.67M |
| Pretax Income | - | -16.88M | -21.65M | -19.38M | -19.57M | -19.07M |
| Tax Provision | - | 503.00K | 762.00K | 642.00K | -395.00K | 253.00K |
| Net Income | - | -17.39M | -22.41M | -20.02M | -19.18M | -19.32M |
| Diluted EPS | - | -0.26 | -0.33 | -0.30 | -0.28 | -0.27 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 47.56M | 62.37M | 65.17M | 77.27M |
| Cost of Revenue | 16.31M | 19.46M | 21.24M | 25.19M |
| Gross Profit | 31.25M | 42.91M | 43.94M | 52.08M |
| Operating Expenses | 119.08M | 117.74M | 110.50M | 122.98M |
| Operating Income | -87.82M | -74.83M | -66.57M | -70.91M |
| EBITDA | -81.38M | -69.57M | -50.76M | -63.40M |
| Interest Expense | 639.00K | 588.00K | 1.91M | 4.55M |
| Pretax Income | -87.58M | -78.50M | -61.27M | -77.49M |
| Tax Provision | -136.00K | 486.00K | 1.22M | 1.51M |
| Net Income | -87.45M | -78.98M | -62.49M | -79.00M |
| Diluted EPS | -1.36 | -1.22 | -0.95 | -1.17 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 243.84M | 206.16M | 155.31M | 163.03M |
| Current Assets | - | 196.25M | 148.05M | 99.41M | 99.08M |
| Cash & Equivalents | - | 161.31M | 123.25M | 80.23M | 70.29M |
| Inventory | - | 5.16M | 6.48M | 5.87M | 6.35M |
| Receivables | - | 6.06M | 10.26M | 7.09M | 14.40M |
| Total Liabilities | - | 43.71M | 54.71M | 58.82M | 115.89M |
| Current Liabilities | - | 26.81M | 35.62M | 26.80M | 50.53M |
| Long Term Debt | - | - | - | 13.24M | 47.73M |
| Total Debt | - | 16.74M | 18.60M | 30.03M | 63.02M |
| Total Equity | - | 200.13M | 151.44M | 96.49M | 47.15M |
| Shares Outstanding | - | 66.40M | 76.90M | 79.32M | 89.32M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -70.09M | -53.22M | -44.52M | -35.89M |
| Investing Cash Flow | - | 41.97M | 12.97M | -4.75M | -8.67M |
| Financing Cash Flow | - | -1.57M | -2.82M | 9.86M | 30.18M |
| Capital Expenditure | - | -10.38M | -9.23M | -8.18M | -8.62M |
| Free Cash Flow | - | -80.47M | -62.45M | -52.69M | -44.51M |
| Net Change in Cash | - | -29.69M | -43.07M | -39.41M | -14.39M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 65.7% | 68.8% | 67.4% | 67.4% |
| Operating Margin % | -184.7% | -120.0% | -102.1% | -91.8% |
| Net Margin % | -183.9% | -126.6% | -95.9% | -102.2% |
| ROE % | -43.7% | -52.2% | -64.8% | -167.6% |
| ROCE % | -40.5% | -43.9% | -51.8% | -63.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SOPH
SOPH Stock Heads For Best Day In Over 8 Months – What’s Driving Today’s Super Rally? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPVFVuNG9lMTFSUDc4ZWx4NVp6dUpvbUdhMWsya0thTmtzQ2JuVXJXcy03eURNbmM2QlBYMVA2NW5pcTVYa2FIb1FNWkxnanI2c080ekp4SXctU0YzOVEyeUtXeC1rLU1WNW44dDZFVUcxWmlXbHB0c3J2X3J3QmJuU1FSek9nTWduWXRiQ1…
BTIG Research Issues Positive Forecast for SOPHiA GENETICS (NASDAQ:SOPH) Stock Price - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxPdWdnaVZqMnh3SWtKTUdqbkprTUdIajR4T1dsS3g2WjZVRnNYZEYybzFvSS16N3NQSFBkeFM4bFAtaFcwSEZ3WFZWUl9VUDVSemlxRnRrNThBZTUycG1udjRSMEJpdVF0VzFrQ05ZYV9GQTRwZmFlUWFLREd0RE02VmxsODV6eXF2SDRpZ3…
SOPHiA GENETICS (SOPH) Stock Jumps On Faster Growth And Higher Outlook - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxONUh3NFFRMFBvQ2xGY19uN2I2V2xscWdDZjkyMUlxWW9GRlNzMEJ6M2VySU1TbTZHSldnR3J6WWNaOGNtVGgxWjAtbnlwblQzWFlEMF9fbWlzeGtFMHlJZlk2RWg0ZkxIMy04RFcwZ3dtQ0gydnJUV3lmT2dINC1zTmRzQ3A3QXc1LXRMYU…
$SOPH stock is up 12% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQWXV5ZUhnRHlKbnN2WmtBUkxqN3BieFRrcjdoNWNDTzJZWUtIS0x3c09MWUZqRVIwcWVvS0tvdHV3WlBVN2VMTzN3aGVQS0tNZk1odGh1WXB1aU5LcWZUa1pBdWhFTXZkMGc5U1hGYXJoeUtodHpPeTFHT2RhZXZENFl4T3p6Y1pZby1BVm…
SOPHiA GENETICS (SOPH) insider Zhenyu Xu plans 10,000-share stock sale - Stock Titan
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPV2FOM05CUEhhX1R2bm93RjRuUjFLOThacDlLaERNRm4wMUJIZTk0cTJxQUpvd0pvOXRfZG1UTVBBSzROS3hSWVhDamttc2dlREJHQmg4MU0tcnF0V3I3NEI3Rzh4MmFVcEtBUzc4UVBxd3dTc0hiS0R5MmpORHBFbFc3RWNTNUduZEdzMm…
SOPHiA GENETICS (NASDAQ:SOPH) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxOWUxPN2w2NFBmNXU2ek5waEoyRmJmX1RuM3VBMWRIYXg0WWUtWXZRTFNoYktGSjZMUlNneDZLUF9tUGhuUDZDeC0wSmhKNGJTR2hiMm55UXo0VEFHV0JPZFd3emN2aWYwbnJYMi1CWEp5SzE0R3RuQlZYZy14a28wNEd0ZThrZnFCS3J5OH…
SOPH — Frequently Asked Questions
What is the current share price of SOPH?
As of 2026-08-05 17:25 PDT, SOPH trades at $6.30 on NASDAQ/NYSE. Its 52-week range is $3.01 to $6.84.
What is the market capitalisation of SOPH?
SOPH has a market capitalisation of $562.72M on NASDAQ/NYSE.
What is the P/E ratio of SOPH?
SOPH trades at a trailing price-to-earnings (P/E) ratio of -5.38. Its price-to-book (P/B) ratio is 11.94.
Is SOPH a good stock to buy?
This page provides a data-driven analysis of SOPH, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.